Delivery Order SPE2DB20D2104-SPE2DB25FMXMS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,774.43 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count packages) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed under a non-set-aside designation. The award is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $2,832.16 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Entecavir 0.5 mg tablets in a 30-count package. This is a firm fixed-price, non-set-aside contract with a completion date of July 22, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $2,516.79 delivery order to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by June 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate office location. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,691.55 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) with a firm fixed price contract type and an ultimate completion date of September 16, 2025. This non-set-aside, competitively awarded delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a ceiling value of $1,650.08 under a firm fixed price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Entecavir 0.5 mg tablets (30-count package) with a ceiling value of $1,337.46. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was not designated as a set-aside contract, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $6,742.70 and a completion date of August 19, 2025. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $1,550.28. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively bid. The contract calls for completion by September 8, 2025, and the work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units) with a ceiling value of $3,232.48 and a firm fixed price. This is a non-set-aside competitive award with an ultimate completion date of June 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,561.03 firm fixed price delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count) on September 8, 2025, with completion scheduled for September 9, 2025. This is a non-set-aside competitive award issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical supply vehicle running through December 2026. The product will be delivered to...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXMSDelivery Order
The Defense Logistics Agency awarded a $1,996.61 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, consistent with AmerisourceBergen's typical federal procurement profile. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical support vehicle enables the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has established itself as a critical federal vendor through its extensive portfolio of competitively awarded contracts covering diverse therapeutic domains and delivery requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 8/11/25 |